Literature DB >> 22987690

Comparison of analysis approaches for phase III clinical trials in amyotrophic lateral sclerosis.

Brian C Healy1, David Schoenfeld.   

Abstract

INTRODUCTION: In this study we explore several methods for incorporating survival information in the analysis of Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) scores.
METHODS: ALSFRS scores and patient survival times were simulated based on estimates from a recent clinical trial. Six analysis approaches were applied to the data. Each approach was based on ALSFRS scores, the survival time, or a combination of the 2. The power of each approach to detect potential treatment effects was estimated.
RESULTS: When the treatment acted solely on the change in ALSFRS, the shared parameter model provided the most power, although all of the models based on random effects were similar. As the effect on survival increased, rank-based analysis showed potential gains in power. Survival analysis was superior under a small effect on ALSFRS and a larger effect on mortality.
CONCLUSIONS: The shared parameter model and rank-based approach can offer improvements in power over traditional approaches.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22987690     DOI: 10.1002/mus.23392

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  9 in total

Review 1.  Concise review: Stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future.

Authors:  J Simon Lunn; Stacey A Sakowski; Eva L Feldman
Journal:  Stem Cells       Date:  2014-05       Impact factor: 6.277

Review 2.  Mesenchymal stem cell therapy for cirrhosis: Present and future perspectives.

Authors:  Young Woo Eom; Gaeun Kim; Soon Koo Baik
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

3.  Global rank tests for multiple, possibly censored, outcomes.

Authors:  Ritesh Ramchandani; David A Schoenfeld; Dianne M Finkelstein
Journal:  Biometrics       Date:  2016-01-26       Impact factor: 2.571

Review 4.  Mesenchymal stem cell therapy for liver fibrosis.

Authors:  Young Woo Eom; Kwang Yong Shim; Soon Koo Baik
Journal:  Korean J Intern Med       Date:  2015-08-27       Impact factor: 2.884

5.  Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis.

Authors:  Leonard H van den Berg; Stavros Nikolakopoulos; Ruben Pa van Eijk; Marinus Jc Eijkemans; Dimitris Rizopoulos
Journal:  Clin Epidemiol       Date:  2018-03-19       Impact factor: 4.790

6.  A machine-learning based objective measure for ALS disease severity.

Authors:  Fernando G Vieira; Subhashini Venugopalan; Alan S Premasiri; Maeve McNally; Aren Jansen; Kevin McCloskey; Michael P Brenner; Steven Perrin
Journal:  NPJ Digit Med       Date:  2022-04-08

Review 7.  Functional Loss and Mortality in Randomized Clinical Trials for Amyotrophic Lateral Sclerosis: To Combine, or Not to Combine-That is the Estimand.

Authors:  Ruben P A van Eijk; Kit C B Roes; Inez de Greef-van der Sandt; Leonard H van den Berg; Ying Lu
Journal:  Clin Pharmacol Ther       Date:  2022-02-17       Impact factor: 6.903

8.  A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.

Authors:  Andrew McGarry; Michael McDermott; Karl Kieburtz; Elisabeth A de Blieck; Flint Beal; Karen Marder; Christopher Ross; Ira Shoulson; Peter Gilbert; William M Mallonee; Mark Guttman; Joanne Wojcieszek; Rajeev Kumar; Mark S LeDoux; Mary Jenkins; H Diana Rosas; Martha Nance; Kevin Biglan; Peter Como; Richard M Dubinsky; Kathleen M Shannon; Padraig O'Suilleabhain; Kelvin Chou; Francis Walker; Wayne Martin; Vicki L Wheelock; Elizabeth McCusker; Joseph Jankovic; Carlos Singer; Juan Sanchez-Ramos; Burton Scott; Oksana Suchowersky; Stewart A Factor; Donald S Higgins; Eric Molho; Fredy Revilla; John N Caviness; Joseph H Friedman; Joel S Perlmutter; Andrew Feigin; Karen Anderson; Ramon Rodriguez; Nikolaus R McFarland; Russell L Margolis; Eric S Farbman; Lynn A Raymond; Valerie Suski; Sandra Kostyk; Amy Colcher; Lauren Seeberger; Eric Epping; Sherali Esmail; Nancy Diaz; Wai Lun Alan Fung; Alan Diamond; Samuel Frank; Philip Hanna; Neal Hermanowicz; Leon S Dure; Merit Cudkowicz
Journal:  Neurology       Date:  2016-12-02       Impact factor: 9.910

9.  Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes.

Authors:  Eva L Feldman; Nicholas M Boulis; Junguk Hur; Karl Johe; Seward B Rutkove; Thais Federici; Meraida Polak; Jane Bordeau; Stacey A Sakowski; Jonathan D Glass
Journal:  Ann Neurol       Date:  2014-03-07       Impact factor: 10.422

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.